The company provided updates for its study programs for 2024, with a focus on its glucagon-like peptide-1 (“GLP-1”) agonist research program, targeting a significant step up in addressing worldwide ...

The FDA declared the tirzepatide shortage over in October 2023, but a lawsuit by Outsourcing Facilities Association, a trade ...

The following is a summary of “Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity,” published in the ...

Undiagnosed or untreated EPI could result in muscle loss since the patient isn’t absorbing the necessary nutrients.

All products are independently selected by our editors. If you buy something, we may earn an affiliate commission.

Consumers who take copies of the weight loss drug Zepbound and diabetes drug Mounjaro will need to find a new source for ...

"An MDL that encompassed any potential injury relating to use of these exceedingly popular weight loss drugs might quickly ...

A new guideline recommends prescribing metformin when initiating an antipsychotic to help mitigate weight gain in certain ...

The underperformance persists despite a 22.6% earnings compounded annual growth rate (CAGR) expected between FY20 and FY25F ...

The expansive roles of gut peptides suggest they may be leveraged in a variety of applied research domains. Their modular structure, receptor-specificity, and potential bioactivity make them ...

The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 ...

The latest buzz around the popular weight loss drugs Ozempic, Mounjaro and Wegovy is to reduce the doseage to avoid the ...